


Ask a doctor about a prescription for POTASSIUM KABI 0.04 mEq/mL in 5% GLUCOSE SOLUTION FOR INFUSION
Package Leaflet: Information for the User
Potassium Kabi 0.04 mEq/ml in Glucose 5% Solution for Infusion EFG
potassium chloride, glucose (as monohydrate)
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack:
Potassium Kabi 0.04 mEq/ml in Glucose 5% is a solution of potassium chloride and glucose in water. Potassium chloride is a chemical substance (often referred to as "salt") found in the blood. Glucose is one of the body's sources of energy. This solution provides 200 kilocalories per liter.
This medicine is used as a source of carbohydrates (sugar) in the prevention and treatment of:
You should not be given Potassium Kabi 0.04 mEq/ml in Glucose 5%:
Warnings and precautions
This medicine has a higher concentration than blood (hypertonic solution). Your doctor will take this into account when calculating the amount to be administered.
Tell your doctor or nurse before you are given Potassium Kabi 0.04 mEq/ml in Glucose 5% if:
This may increase the risk of low sodium levels in the blood and may cause headache, nausea, seizures, lethargy, coma, brain swelling, and death. Brain swelling increases the risk of death and brain damage. People at higher risk of brain swelling are:
Your doctor will closely monitor you while you are being given this medicine. Your doctor will take blood and urine samples to check your condition. Special attention will be paid if you have heart or kidney problems.
Your doctor should take into account if you are receiving parenteral nutrition (nutrition administered by infusion into a vein). You may need to be given extra nutrition during long-term treatment with Potassium Kabi 0.04 mEq/ml in Glucose 5%.
Since the infusion of Potassium Kabi 0.04 mEq/ml in Glucose 5% contains sugar (glucose), this may cause an increase in blood sugar levels (hyperglycemia). If this happens, your doctor may:
This is especially important if you are diabetic.
All patients must be closely monitored. In cases where normal regulation of blood water content is altered due to increased secretion of antidiuretic hormone (ADH), infusion of fluids with low sodium chloride concentration (hypotonic fluids) may result in low sodium levels in the blood (hyponatremia). This may cause headache, nausea, seizures, lethargy, coma, brain swelling, and death; therefore, these symptoms (symptomatic acute hyponatremic encephalopathy) are considered a medical emergency.
Children
The infusion of Potassium Kabi 0.04 mEq/ml in Glucose 5% should be administered with special caution in children.
Newborns, especially premature and low-birth-weight infants, are at higher risk of developing low or high blood sugar levels(hypoglycemia or hyperglycemia) due to glucose solution infusion.
Use of Potassium Kabi 0.04 mEq/ml in Glucose 5% with other medicines
Tell your doctor or nurse if you are using, have recently used, or might use any other medicines.
It is especially important to tell your doctor if you are taking:
Potassium Kabi 0.04 mEq/ml in Glucose 5% should not be administered through the same route as a blood transfusion. This may damage the red blood cells or cause them to clump.
Use of Potassium Kabi 0.04 mEq/ml in Glucose 5% with food and drinks
You should ask your doctor what you can eat or drink.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or nurse for advice before using this medicine.
This medicine can be used during pregnancy and breastfeeding. Your doctor will closely monitor the amount of medicine to be administered. Your doctor will also take blood samples to check the levels of chemical substances in the blood, as changes in potassium levels in the blood can affect your heart and your baby's heart.
This medicine should be administered with special caution to pregnant women during labor, especially if combined with oxytocin (a hormone that can be administered to induce labor and control bleeding) due to the risk of hyponatremia.
Driving and using machines
This medicine does not affect your ability to drive or use machines.
This medicine should be administered by a doctor or nurse.
Your doctor will decide what dose you need and when it will be administered, depending on your age, weight, clinical and biological condition, hydration status, and reason for treatment. The dose to be administered may also be affected by other treatments you are receiving.
Before and during infusion, your doctor will monitor the amount of fluid in your body, blood acidity, urine flow, and electrolyte levels (especially sodium) in your blood (mainly in patients with high levels of vasopressin or taking other medicines that increase the effects of vasopressin).
The infusion rate will be determined by your doctor.
If you need a high volume or rapid infusion of this medicine, your doctor will monitor your ECG (heart activity).
During treatment with Potassium Kabi 0.04 mEq/ml in Glucose 5%, your doctor will take blood samples to check your levels of:
If you have kidney failure, you will receive a lower dose.
If you are given more Potassium Kabi 0.04 mEq/ml in Glucose 5% than you should
If you are given too much of this medicine (overdose), you may experience:
If you notice any of these symptoms, you should tell your doctor immediately. The medicine will be stopped and you will be treated depending on the symptoms.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The frequency of side effects is unknown.
Tell your doctor or nurse if you get any of the following side effects.
Side effects that may occur due to the administration technique include:
Reporting of side effects
If you experience any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Agency's online platform: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
This medicine does not require special storage conditions.
Do not use this medicine after the expiry date stated on the vial. The expiry date is the last day of the month stated.
Do not use this medicine if the solution is not clear or has visible particles. Do not use this medicine if the packaging is damaged.
Composition of Potassium Kabi 0.04 mEq/ml in Glucose 5%
Appearance of the Product and Container Content
Potassium Kabi 0.04 mEq/ml in Glucose 5% is a clear, particle-free solution. It is available in low-density polyethylene vials of 500 and 1000 ml, closed with a polyolefin cap that contains a polyisoprene rubber stopper. It is supplied in packs of 10 vials.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Fresenius Kabi España, S.A.U.
C/ Marina, 16-18
08005 Barcelona
Manufacturer
Labesfal – Laboratorios Almiro, S.A.
Zona Industrial do Lagedo, Santiago de Besteiros, 3465 – 157
Portugal
This Medicinal Product is Authorized in the Member States of the European Economic Area Under the Following Names:
Member State Name | Medicinal Product Name |
Belgium | Potassium Chloride 0.3% + Glucose 5% Fresenius Kabi |
Bulgaria | ?????? ?????? + ??????? ???? 3 mg/ml + 50 mg/ml ?????????? ??????? |
Estonia | Potassium Chloride/Glucose Fresenius 3 mg/50 mg/ml |
France | Potassium Chloride 0.3% and Glucose 5% Kabi, Solution for Infusion |
Ireland | Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution for Infusion |
Latvia | Potassium Chloride/Glucose Fresenius 3 mg/50 mg/ml Solution for Infusion |
Lithuania | Potassium Chloride/Glucose Fresenius 3 mg/50 mg/ml Infusion Solution |
Poland | Potassium Chloride 0.3% + Glucose 5% Kabi |
Portugal | Potassium Chloride 0.3% w/v and Glucose 5% w/v Kabi |
Slovenia | Potassium Chloride/Glucose Kabi 3 mg/50 mg/ml Solution for Infusion |
Spain | Potassium Kabi 0.04 mEq/ml in Glucose 5% Solution for Infusion |
Netherlands | Potassium Chloride 0.3% + Glucose 5% Fresenius Kabi |
United Kingdom | Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution for Infusion |
Date of Last Revision of this Leaflet: June 2018
This information is intended only for healthcare professionals:
Handling and Preparation
This product is for single use. Any unused solution should be discarded.
Use only if the solution is clear, particle-free, and the container is not damaged.
Route of Administration
Administration is by intravenous route using sterile and apyrogenic equipment.
Potassium should be administered intravenously through a large peripheral vein or central vein to reduce the risk of sclerosis. If perfused through a central vein, ensure that the catheter is not in the atrium or ventricle to avoid localized hyperkalemia.
Solutions containing potassium should be administered slowly.
Administration Rate
Potassium should not be administered intravenously at a rate greater than 15 to 20 mmol per hour to avoid dangerous hyperkalemia.
In no case should the dose indicated in the "General Posology" section be exceeded.
Posology
General Advice
It may be necessary to monitor water balance, serum glucose, serum sodium, and other electrolytes before and during administration, especially in patients with increased release of non-osmotic vasopressin (syndrome of inappropriate antidiuretic hormone secretion, SIADH) and in patients co-medicated with vasopressin agonist medications due to the risk of hyponatremia. Monitoring of serum sodium is particularly important for physiologically hypotonic fluids. Potassium 0.04 mEq/ml in Glucose 5% solution for infusion may become extremely hypotonic after administration due to glucose metabolism in the body.
General Posology
The recommended dose for the treatment of fluid and carbohydrate depletion is:
from 0 to 10 kg body weight: 100 ml/kg/24 hours
from 10 to 20 kg body weight: 1000 ml + (50 ml/kg above 10 kg)/24 hours
> 20 kg body weight: 1500 ml + (20 ml/kg above 20 kg)/24 hours
Posology for the Prevention and Treatment of Potassium Depletion
Typical doses of potassium for the prevention of hypokalemia may be up to 50 mmol daily, and similar doses may be suitable in moderate potassium deficiencies. The maximum recommended dose of potassium is 2 to 3 mmol/kg every 24 hours.
When used for the treatment of hypokalemia, the recommended dose is 20 mmol of potassium in 2 or 3 hours (e.g., 7-10 mmol per hour) under electrocardiographic control (ECG).
The maximum recommended administration rate should not exceed 15 to 20 mmol per hour.
Patients with renal insufficiency should receive lower doses.
In no case should the dose indicated in "General Posology" be exceeded.
Use in the Pediatric Population
When used for the treatment of hypokalemia, the recommended dose is 0.3 - 0.5 mmol/kg/body weight/hour. The dose should be adjusted according to laboratory values obtained routinely.
The maximum recommended dose of potassium is 2 to 3 mmol/kg/body weight/day.
The rate and volume of infusion depend on the age, weight, clinical, and metabolic conditions of the patient, concomitant treatment, and should be determined by a physician experienced in intravenous fluid therapy for pediatric patients.
Validity Period After First Opening:
The stability of the product after first opening has not been evaluated; therefore, the product must be used immediately after first opening.
Validity Period in Use (with Additives):
Before use, the physical and chemical stability of any added medication should be established at the pH of Potassium Kabi 0.04 mEq/ml in Glucose 5% solution for infusion.
In the absence of compatibility studies, this medicinal product should not be mixed with other medications.
It is the responsibility of the physician to assess the incompatibility of the added medication with the Potassium Kabi 0.04 mEq/ml in Glucose 5% solution, controlling for possible changes in color and/or the formation of precipitates, insoluble complexes, or crystal appearance. The summary of product characteristics of the medications to be added should also be consulted.
Before adding a medication, it should be verified that it is soluble and/or stable in water at the pH of Potassium Kabi 0.04 mEq/ml in Glucose 5% solution for infusion (pH: 3.5 to 6.0).
As a guide, the following medications are incompatible with the Potassium Kabi 0.04 mEq/ml in Glucose 5% solution, although this list is not exhaustive:
Additives known to be incompatible should not be used.
From a microbiological point of view, mixtures of this medicinal product with other medicinal products should be used immediately, unless the mixture has been prepared in controlled and validated aseptic conditions. If not used immediately, the conditions and storage times during use are the responsibility of the user.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for POTASSIUM KABI 0.04 mEq/mL in 5% GLUCOSE SOLUTION FOR INFUSION – subject to medical assessment and local rules.